Kidney Transplantation Recipients
Conditions
Keywords
Kidney transplantation, genotype, tacrolimus, CYP3A5
Brief summary
Tacrolimus dose highly varies among Asian kidney transplant recipients. This can be explained by variety of CYP3A5 expression. CYP3A5 genotyping is highly recommended for patients receiving tacrolimus. Here, we assessed the tacrolimus dose prediction by comparing CYP3A5 expression and tacrolimus dosage using tacrolimus concentration after single dose administration prior to kidney transplantation. Plasma tacrolimus trough level was measured at 12 hours after first dose of 0.1 mg/kg of tacrolimus (TacC12), orally administered in 51 new kidney transplant recipients. Patients with CYP3A5 inhibitor/inducer co-medications were excluded. Genotyping for CYP3A5 expression were carried out by RT-PCR. The dosages of tacrolimus at post-operative day 7 and dosage which provided stable therapeutic levels in post-operative month 1 to 3 (C0 5-8 ng/mL) were recorded. The genotyping, TacC12, and target tacrolimus dosage have good correlations.
Interventions
DRUGTacrolimus C12
Sponsors
Chulalongkorn University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All KT recipients
Exclusion criteria
* Recipient who not receiving tacrolimus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| target tacrolimus dose at 3 months | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| rate of rejection | 3-12 months |
| rate of CNI toxicity | 2-12 months |
Countries
Thailand
Contacts
Primary ContactNatavudh Townamchai, MD
Outcome results
None listed